The safety of Chinese medicine and its rational application in nephropathy

doi:10.3877/cma.j.issn.2095-3216.2018.01.001

Abstract

Abstract:

Chinese medicine is the precious wealth of our country, plays an important role in the treatment of many complicated diseases, and is commonly used worldwide for preventive and therapeutic purposes during recent decades. However, the safety of herbal products has been widely questioned, especially their potential nephrotoxicity. In the use of Chinese medicine, we still need to attach great attention to its adverse reactions. Since most drugs are excreted by the kidney, drug-induced renal damage is always a deeply-concerned issue among clinicians. To ensure rational application of Chinese medicine in kidney diseases, we should make prescriptions under the guidance of traditional Chinese medicine (TCM) theory, provide individualized treatment options in accordance with patients′ constitution and basic diseases, select drug sources and processing technology reasonably, and strictly control the dosage and course of therapy.

Key words: Chinese medicine, Toxic and side effects, Kidney disease, Rational use of drug

Ping Li, Jiaoyi Chen, Dandan Li. The safety of Chinese medicine and its rational application in nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2018, 07(01): 1-3.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2018.01.001

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2018/V07/I01/1

References 16

[1]	Hong CD. Complementary and alternative medicine in Korea: current status and future prospects [J]. J Altern Complement Med, 2001, 7(Suppl 1): 33-40.
[2]	Chen FP, Chen TJ, Kung YY, et al. Use frequency of traditional Chinese medicine in Taiwan [J]. BMC Health Serv Res, 2007, 7(1): 1-11.
[3]	Eisenberg D, Davis R, Ettner S. Trends in alternative medicine use in the United States [J]. JAMA, 1997, 280(6): 370-371.
[4]	Yamashita H, Tsukayama H, Sugishita C. Popularity of complementary and alternative medicine in Japan: a telephone survey [J]. Complement Ther Med, 2002, 10(2): 84-93.
[5]	Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem [J]. Kidney Int, 2008, 74(2): 158-169.
[6]	Ingsathit A, Thakkinstian A, Chaiprasert A, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study [J]. Nephrol Dial Transplant, 2010, 25(5): 1567-1575.
[7]	冯雪，方赛男，高雨鑫，等. 中药肾毒性国内外研究现状[J]. 中国中药杂志，2018, 43(3): 417-424.
[8]	Lai MN, Lai JN, Chen PC, et al. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study [J]. Am J Kidney Dis, 2010, 55(3): 507-518.
[9]	关建红，翁维良. 对中药"毒性"与毒性分级的思考[J]. 中国中药杂志，2008, 33(4): 485-487.
[10]	Loh AH, Cohen AH. Drug-induced kidney disease-pathology and current concepts [J]. Ann Acad Med Singapore, 2009, 38(3): 240-250.
[11]	Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney [J]. Kidney Int, 2000, 58(3): 944-958.
[12]	张松波，周宏灏. 药物代谢性别差异及与核受体的关系[J]. 中国药理学通报，2007, 23(3): 292-294.
[13]	Schlender JF, Vozmediano V, Golden AG, et al. Current strategies to streamline pharmacotherapy for older adults [J]. Eur J Pharm Sci, 2017, 111: 432-442.
[14]	时琳，薛颖. 含毒性成分中成药的应用探讨[J]. 中成药，2015, 37(7): 1626-1629.
[15]	阳长明. 乌头碱类成分中药制剂质量控制探讨[J]. 药品评价，2011, 8(10): 23-27.
[16]	李娆娆，张志杰，王祝举，等. 近60年中药毒副作用及不良反应文献分析[J]. 中国实验方剂学杂志，2010, 16(15): 213-216，221.

Please choose a citation manager

Content to export